Use of Autoantibodies to Detect the Onset of Breast Cancer
The widespread use of screening mammography has resulted in increased detection of early-stage breast disease, particularly for in situ carcinoma and early-stage breast cancer. However, the majority of women with abnormalities noted on screening mammograms are not diagnosed with cancer because of se...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2014/574981 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560223666044928 |
|---|---|
| author | Jérôme Lacombe Alain Mangé Jérôme Solassol |
| author_facet | Jérôme Lacombe Alain Mangé Jérôme Solassol |
| author_sort | Jérôme Lacombe |
| collection | DOAJ |
| description | The widespread use of screening mammography has resulted in increased detection of early-stage breast disease, particularly for in situ carcinoma and early-stage breast cancer. However, the majority of women with abnormalities noted on screening mammograms are not diagnosed with cancer because of several factors, including radiologist assessment, patient age, breast density, malpractice concerns, and quality control procedures. Although magnetic resonance imaging is a highly sensitive detection tool that has become standard for women at very high risk of developing breast cancer, it lacks sufficient specificity and costeffectiveness for use as a general screening tool. Therefore, there is an important need to improve screening and diagnosis of early-invasive and noninvasive tumors, that is, in situ carcinoma. The great potential for molecular tools to improve breast cancer outcomes based on early diagnosis has driven the search for diagnostic biomarkers. Identification of tumor-specific markers capable of eliciting an immune response in the early stages of tumor development seems to provide an effective approach for early diagnosis. The aim of this review is to describe several autoantibodies identified during breast cancer diagnosis. We will focus on these molecules highlighted in the past two years and discuss the potential future use of autoantibodies as biomarkers of early-stage breast cancer. |
| format | Article |
| id | doaj-art-0362a494147c4391bc54ca8e5324b8fb |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-0362a494147c4391bc54ca8e5324b8fb2025-02-03T01:28:00ZengWileyJournal of Immunology Research2314-88612314-71562014-01-01201410.1155/2014/574981574981Use of Autoantibodies to Detect the Onset of Breast CancerJérôme Lacombe0Alain Mangé1Jérôme Solassol2INSERM-U896, Montpellier Cancer Research Institute (IRCM), 34298 Montpellier Cedex 5, FranceDepartment of Biopathology, CHU Montpellier, 34295 Montpellier Cedex 5, FranceDepartment of Biopathology, CHU Montpellier, 34295 Montpellier Cedex 5, FranceThe widespread use of screening mammography has resulted in increased detection of early-stage breast disease, particularly for in situ carcinoma and early-stage breast cancer. However, the majority of women with abnormalities noted on screening mammograms are not diagnosed with cancer because of several factors, including radiologist assessment, patient age, breast density, malpractice concerns, and quality control procedures. Although magnetic resonance imaging is a highly sensitive detection tool that has become standard for women at very high risk of developing breast cancer, it lacks sufficient specificity and costeffectiveness for use as a general screening tool. Therefore, there is an important need to improve screening and diagnosis of early-invasive and noninvasive tumors, that is, in situ carcinoma. The great potential for molecular tools to improve breast cancer outcomes based on early diagnosis has driven the search for diagnostic biomarkers. Identification of tumor-specific markers capable of eliciting an immune response in the early stages of tumor development seems to provide an effective approach for early diagnosis. The aim of this review is to describe several autoantibodies identified during breast cancer diagnosis. We will focus on these molecules highlighted in the past two years and discuss the potential future use of autoantibodies as biomarkers of early-stage breast cancer.http://dx.doi.org/10.1155/2014/574981 |
| spellingShingle | Jérôme Lacombe Alain Mangé Jérôme Solassol Use of Autoantibodies to Detect the Onset of Breast Cancer Journal of Immunology Research |
| title | Use of Autoantibodies to Detect the Onset of Breast Cancer |
| title_full | Use of Autoantibodies to Detect the Onset of Breast Cancer |
| title_fullStr | Use of Autoantibodies to Detect the Onset of Breast Cancer |
| title_full_unstemmed | Use of Autoantibodies to Detect the Onset of Breast Cancer |
| title_short | Use of Autoantibodies to Detect the Onset of Breast Cancer |
| title_sort | use of autoantibodies to detect the onset of breast cancer |
| url | http://dx.doi.org/10.1155/2014/574981 |
| work_keys_str_mv | AT jeromelacombe useofautoantibodiestodetecttheonsetofbreastcancer AT alainmange useofautoantibodiestodetecttheonsetofbreastcancer AT jeromesolassol useofautoantibodiestodetecttheonsetofbreastcancer |